Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis.

Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis.

Item
http://www.wikidata.org/entity/Q35915140
Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerationsRisk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.Imatinib attenuates cardiac fibrosis by inhibiting platelet-derived growth factor receptors activation in isoproterenol induced model.FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).The Safety of Bosutinib for the Treatment of Chronic Myeloid Leukemia.Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.Mobile Health Intervention to Increase Oral Cancer Therapy Adherence in Patients With Chronic Myeloid Leukemia (The REMIND System): Clinical Feasibility and Acceptability Assessment.Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.Association between a cardiovascular disease risk assessment and the molecular response to tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia patients.Mechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis
P2860

Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis.

Item
http://www.wikidata.org/entity/Q35915140
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Association Between BCR-ABL Ty ...... atic Review and Meta-analysis.
@ast
Association Between BCR-ABL Ty ...... atic Review and Meta-analysis.
@en
type
label
Association Between BCR-ABL Ty ...... atic Review and Meta-analysis.
@ast
Association Between BCR-ABL Ty ...... atic Review and Meta-analysis.
@en
prefLabel
Association Between BCR-ABL Ty ...... atic Review and Meta-analysis.
@ast
Association Between BCR-ABL Ty ...... atic Review and Meta-analysis.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P356
P1433
P1476
Association Between BCR-ABL Ty ...... atic Review and Meta-analysis.
@en
P2093
P304
P31
P356
10.1001/JAMAONCOL.2015.5932
P433
P478
P50
P577
P5875
P698
P921